Oral Session 3-12D MPN: Clinical

[OS3-12D-6] High JAK2 allele burden patients have risk of low vWF activity even with well-controlled platelets

Kazuhide Iizuka^1,2,3, Noriyoshi Iriyama¹, Soji Morishita^3,5, Katsuhiro Miura¹, Yoshikazu Iizuka¹, Yuji Nishizaki⁴, Naotake Yanagisawa⁴, Jun Ando³, Yoshihito Uchino¹, Hiromichi Takahashi^1,2, Masaru Nakagawa¹, Takashi Hamada¹, Yoshihiro Hatta¹, Tomohiro Nakayama², Masami Takei¹, Norio Komatsu³ (1.Hematology and Rheumatology, Nihon Univ., Tokyo, Japan, 2.Laboratory Medicine, Nihon Univ., Tokyo, Japan, 3.Hematology, Juntendo Univ., Tokyo, Japan, 4.Medical Technology Innovation Center, Juntendo Univ., Tokyo, Japan, 5.Transfusion Medicine and Stem Cell Regulation, Juntendo Univ, Tokyo, Japan)